Zhifei’s Record Growth Crumbles: 2025 Losses and 2026 Revenue Decline Shock Investors
Zhifei’s record‑breaking 2025 losses reveal a vaccine company in crisis, with shrinking revenue, heavy reliance on licensed products, and a long‑term R&D pipeline that may or may not turn profitability back on the horizon.
4 minutes to read